Abstract

Many pathogens enter the host via the gut, causing disease in animals and humans. A robust intestinal immune response is necessary to protect the host from these gut pathogens. Despite being best suited for eliciting intestinal immunity, oral vaccination remains a challenge due to the gastrointestinal environment, a poor uptake of vaccine antigens by the intestinal epithelium and the tolerogenic environment pervading the gut. To improve uptake, efforts have focused on targeting antigens towards the gut mucosa. An interesting target is aminopeptidase N (APN), a conserved membrane protein present on small intestinal epithelial cells shown to mediate epithelial transcytosis. Here, we aimed to further optimize this oral vaccination strategy in a large animal model. Porcine APN-specific monoclonal antibodies were generated and the most promising candidate in terms of epithelial transcytosis was selected to generate antibody fusion constructs, comprising a murine IgG1 or porcine IgA backbone and a low immunogenic antigen: the F18-fimbriated E. coli tip adhesin FedF. Upon oral delivery of these recombinant antibodies in piglets, both mucosal and systemic immune responses were elicited. The presence of the FedF antigen however appeared to reduce these immune responses. Further analysis showed that F18 fimbriae were able to disrupt the antigen presenting capacity of intestinal antigen presenting cells, implying potential tolerogenic effects of FedF. Altogether, these findings show that targeted delivery of molecules to epithelial aminopeptidase N results in their transcytosis and delivery to the gut immune systems. The results provide a solid foundation for the development of oral subunit vaccines to protect against gut pathogens.

Highlights

  • Most pathogens invade the host at the mucosal surfaces, such as the gut

  • The targeting of vaccine antigens towards epithelial cells and antigen presenting cells might be a potential mechanism to increase the efficacy of oral vaccines by interacting with receptors that activate different signaling transduction pathways, circumventing the tolerogenic response and enhancing uptake [7, 30, 31]

  • We evaluated the use of aminopeptidase N (APN)-targeted monoclonal antibodies and recombinant antibody constructs as a delivery system for vaccine antigens

Read more

Summary

Introduction

Most pathogens invade the host at the mucosal surfaces, such as the gut Frontline protection against these enteropathogens requires robust intestinal immune responses at the site of infection, more specific pathogen-specific secretory immunoglobulin A (SIgA) [1]. Without proper activation and correct dosing, tolerance is induced rather than protective immunity [1] To overcome these challenges in oral vaccination, current efforts are focused on different encapsulation strategies to preserve antigen stability in the gut, novel mucosal adjuvants to surmount tolerance or targeting antigens to intestinal cell populations to enhance vaccine uptake [5]. Delivery of antigens and microparticles to aminopeptidase N by different antibody formats facilitated their uptake by the small intestinal epithelium and elicited strong immune responses in piglets upon oral administration [15,16,17,18]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call